Status:
RECRUITING
Liver Damage and Cardiometabolic Disorders in NAFLD
Lead Sponsor:
University of Roma La Sapienza
Conditions:
NAFLD
Liver Fibroses
Eligibility:
All Genders
18-80 years
Brief Summary
Liver fibrosis is the most important prognostic factor in patients with non-alcoholic factor disease. Clinical and biological condition, as diabetes or mutation for PNPLA3, are well known factors asso...
Detailed Description
Non-alcoholic fatty liver disease (NAFLD) is a common liver disease worldwide. NAFLD includes a spectrum of diseases raging from simple steatosis to non-alcoholic steatohepatitis (NASH), cirrhosis and...
Eligibility Criteria
Inclusion
- Patients aged 18 years old or more
- Patients with at least on of the following metabolic disorders
- Obesity
- Diabetes
- Arterial hypertension
- Dyslipidemia
Exclusion
- Average daily consumption of alcohol \>20 g in women and of \>30 g in men (assessed by Alcohol Use Disorders Identification Test, AUDIT;
- presence of hepatitis B surface antigen and antibody to hepatitis C virus;
- positive tests for autoimmune hepatitis;
- cirrhosis and other chronic liver diseases;
- diagnosis of oncological diseases
- concomitant therapy with drugs known to promote liver steatosis (e.g. amiodarone);
- other chronic infectious or autoimmune disease;
Key Trial Info
Start Date :
November 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2036
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT04036357
Start Date
November 1 2011
End Date
December 31 2036
Last Update
August 16 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Day Service of Internal Medicine and Metabolic Disorders - Policlinico Umberto I - Sapienza University of Rome
Rome, Italy, 00100